Not sure how to vote in the congressional elections on November 8?
A great starting point would be the interactive 2016 Congressional Voter Guide released today by Drug Policy Action (the political arm of the Drug Policy Alliance).
The user-friendly site allows you to type in your ZIP code to see how your own US House Representative is rated, based on seven key votes in 2015 and 2016 covering medical marijuana, adult-use marijuana and novel psychoactive substances.
Each Rep. is awarded a grade from “A” (100 percent pro-reform voting record) to “F” (below 20 percent). You can also read a more detailed report on your Representative’s record. (US Senators aren’t graded because there were no relevant votes in the Senate during this period.)
Drug Policy Action has released voter guides before. But encouragingly, this installment awards higher grades than ever: 110 Representatives, or 25 percent of the US House, get an “A”—while 241 Representatives, well over half of the total, get a “C” (at least a 50 percent pro-reform voting record) or better.
Democrats score better than Republicans on average, but the breakdown of those 241 at “C” or above—177 Democrats and 64 Republicans—indicates the extent to which drug policy reform has become a bipartisan issue
Drug Policy Action names its 2016 US House “Champions” as:
Rep. Earl Blumenauer (D-OR/3)
Rep. Suzanne Bonamici (D-OR/1)
Rep. Steve Cohen (D-TN/9)
Rep. John Conyers (D-MI/13)
Rep. Sam Farr (D-CA/20)
Rep. Joe Heck (R-NV/3)
Rep. Hakeem Jeffries (D-NY/8)
Rep. Barbara Lee (D-CA/13)
Rep. Ted Lieu (D-CA/33)
Rep. Thomas Massie (R-KY/4)
Rep. Tom McClintock (R-CA/4)
Rep. Ed Perlmutter (D-CO/7)
Rep. Jared Polis (D-CO/2)
Rep. Dana Rohrabacher (R-CA/48)
Meanwhile the six worst “Drug War Extremists” in the House are named as:
Rep. John Fleming (R-LA/4)
Rep. William Keating (D-MA/9)
Rep. Joseph Kennedy (D-MA/4)
Rep. Joseph Pitts (R-PA/16)
Rep. Harold Rogers (R-KY/5)
Rep. Pete Sessions (R-TX/32)
“Voters have signaled time and again that they want new drug policies grounded in health and science, and elected officials in Congress are finally paying attention,” says Grant Smith, deputy director of national affairs for Drug Policy Action. “We’ve reached the remarkable point where more than half of Representatives in Congress are consistently responding to public opinion and voting in favor of letting states set their own drug policies, yet nearly half of Congress is still ignoring public opinion in favor of drug policy reform. It’s up to voters to let these Representatives know how they feel about their record.”
Check out the voter guide here.
What is China doing to stop Beijing’s new coronavirus outbreak?
Over 1,000 flights have been cancelled, schools shut and residents urged not to leave Beijing, as Chinese authorities race to contain a fresh outbreak linked to the capital's largest wholesale food market.
The number of confirmed cases in the capital has shot up to 137 within the last week after two months of no cases, and four other provinces have revealed cases linked to the Beijing cluster.
How did the outbreak begin, and what measures are Beijing taking to contain it?
- What is the origin of the cluster? -
Beijing had turned into a virtual fortress at the height of the pandemic, with people arriving from other regions or countries required to undergo quarantines.
Democrats and Never-Trumpers gaming out ‘doomsday scenarios’ if president refuses to leave office: report
According to a report in the New York Times, Democratic strategists and Never-Trumper conservatives fear Donald Trump will refuse to leave office should he lose in November and are making plans and figuring out their legal options should such an unprecedented state of affairs come to pass.
The report, by the Times' Reid Epstein, begins with one such possible scenario.
‘Retaliation plain and simple’: Vaccine agency top Doc fired by Trump administration files whistleblower complaint
Dr. Rick Bright has retained an attorney and will be filing a whistleblower complaint after the Trump administration fired him from his position as head of the federal agency charged with developing a COVID-19 vaccine. Dr. Bright was moved to a different agency with a narrower focus after he raised concerns over President Donald Trump's obsession with promoting hydroxychloroquine, a malaria drug recent studies found doubles the death rate in coronavirus patients.